Please assess the completion status of the following clinical trial:

Trial Title: A Multicenter Analysis of Levonorgestrel-Intrauterine System (LNG-IUS) Use in the Postpartum Period

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* All women \>37 weeks gestation who desire LNG-IUS for postpartum contraception who do not have a contraindication as described below will be offered participation in our study.~Exclusion Criteria:~Contraindications to the LNG-IUS include:~* Pregnancy or suspicion of pregnancy~* Congenital or acquired uterine anomaly including fibroids if they distort the uterine cavity~* Postpartum endometritis within the past 3 months~* Known or suspected uterine or cervical neoplasia or unresolved, abnormal pap smear~* untreated acute cervicitis or vaginitis including bacterial vaginosis or other lower genital tract infections~* acute liver disease or liver tumor~* hypersensitivity to any component of the product~* known or suspected carcinoma of the breast~Any of these conditions would exclude the patient from receiving these forms of contraception in our study.~In addition the following intrapartum findings, the following would exclude the patient:~* Delivery \<37 weeks~* Intrapartum chorioamnionitis (defined as maternal fever \>100.4 and two of the following conditions: Maternal leukocytosis (greater than 15,000 cells/cubic millimeter), Maternal tachycardia (greater than 100 beats/minute), Fetal tachycardia (greater than 160 beats/minute), Uterine tenderness, Foul odor of the amniotic fluid~* Postpartum Hemorrhage (defined as \>500cc EBL for spontaneous vaginal delivery or \>1000cc for cesarean delivery)

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: 45 Years
- Healthy Volunteers: t

Study Arms:
- Immediate (Type: EXPERIMENTAL): LNG-IUS insertion within the timeframe of delivery of the placenta to 72 hours postpartum
- Interval (Type: ACTIVE_COMPARATOR): LNG-IUS insertion after 6 weeks postpartum

Based on this trial design, predict the completion outcome and termination type (if applicable).